Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

Haematologica

Volumn 93, Issue 8, 2008, Pages 1263-1265

  Yanada, Masamitsu ^a   Borthakur, Gautam ^a   Ravandi, Farhad ^a   Bueso Ramos, Carlos ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Bone marrow blasts; Complete remission

Indexed keywords

CYTARABINE; FLUDARABINE; IDARUBICIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CELL COUNT; CELL KINETICS; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; CLINICAL DECISION MAKING; DRUG MEGADOSE; HUMAN; LETTER; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELOBLAST; PROBABILITY;

ADULT; BONE MARROW; CYTARABINE; HUMANS; KINETICS; LEUKEMIA, MYELOID, ACUTE; PROBABILITY; REMISSION INDUCTION;

EID: 48749108720     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12825     Document Type: Letter

References (6)

1. The Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (Version 2.2007) [database on the Internet]. Fort Washington, PA, USA. 2006 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org/ professionals/physician_gls/PDF/aml.pdf.
2. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001;98:3575-83.
3. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69-79.
4. Liso V, Albano F, Pastore D, Carluccio P, Mele G, Lamacchia M, et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica 2000;85:1285-90.
5. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003;101: 64-70.
6. Buchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006;24:2480-9.